Sensitization to isobornyl acrylate in a tertiary Belgian hospital.
Allergic contact dermatitis (ACD) to isobornyl acrylate (IBOA) hasbeen largely reported. Consequently, it was recognized as the“Con-tact Allergen of the Year 2020â€by the American Contact DermatitisSociety. The prevalence of IBOA sensitization is estimated to be 0.7%to 3.8% in patients with adverse skin reactions to medical devices(MDs) used in diabetes.1,2However, to our knowledge, the prevalenceof sensitization to IBOA in the general patch-tested population hasnot yet been established. [.]
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2021 |
Verlag/Hrsg.: |
Wiley
|
Schlagwörter: | Acrylates / Allergens / Belgium / Camphanes / Dermatitis / Allergic Contact / Occupational / Female / Humans / Male / Medical Staff / Hospital / Patch Tests / allergic contact dermatitis / glucose sensor / insulin pump / isobornyl acrylate / medical device / sensitization |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26573080 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2078.1/260955 |